Aspirin + ticagrelor

Aspirin + ticagrelor has been studied in 2 papers since 2024: 1 trial and 1 observational study in people. The newest paper, Feb 28, 2025: “Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database”.

Intervention

2 papers study it4 more mention it4 findingsUpdated Feb 28, 2025

PubChem PubChem ChEBI ChEBI

1 new paper in 30 daysSee all 6

“Ticagrelor-aspirin group was associated with lower risks of stroke recurrence within 90 days in younger patients (HR 0.68, 95% CI 0.51 to 0.91, p=0.008)”

Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trialStroke and vascular neurology2024doi:10.1136/svn-2023-002450

1 of its findings points the other way.

2 independent labs in 2 countries
1 finding against

Funders: Beijing Municipal Science and Technology Commission and 7 more
3 of 4 findings with company ties

Human trial1
Humans1

Studies in people

1 study gave aspirin + ticagrelor to people and measured what changed.

down: Lowers the risk of stroke recurrence HR 0.68, 95% CI 0.51 to 0.91
no change: Has no effect on stroke recurrenceHR 1.00, 95% CI 0.49 to 2.06
Randomized trial6,412 people 90 days
Patients with minor stroke or TIA
Stroke and vascular neurology, Jan 30, 2024

What did studies of Aspirin + ticagrelor find?

Studies of Aspirin + ticagrelor measured 1 outcome; the most studied are stroke recurrence (1 study).

Stroke recurrence

no changein humans1HR 1

1 study

Aspirin + ticagrelor showed no clear effect on stroke recurrence in old-old patients (≥80 years) (HR 1.00, 95% CI 0.49 to 2.06).
“old-old patients did not exhibit significant differences for the efficacy and safety outcomes after adjustment, including new stroke within 90 days”
Human trialin old-old patients (≥80 years)90 daysn = 406
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial
Stroke and vascular neurologyJan 30, 2024

What is Aspirin + ticagrelor linked with?

Studies link Aspirin + ticagrelor with 2 measures, most often stroke recurrence (1 study) and mortality (1).

Stroke recurrence

downin humans1HR 0.68

1 study

Aspirin + ticagrelor lowers the risk of stroke recurrence in younger patients (<65 years) (HR 0.68, 95% CI 0.51 to 0.91).
“in younger patients, ticagrelor-aspirin was associated with lower risks of stroke within 90 days”
Human trialin younger patients (<65 years)90 daysn = 3,251
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial
Stroke and vascular neurologyJan 30, 2024
Aspirin + ticagrelor lowers the risk of stroke recurrence in humans (CYP2C19 loss-of-function alleles, minor stroke or high-risk TIA) (HR 0.68, 95% CI 0.51 to 0.91, p=0.008).
“Ticagrelor-aspirin group was associated with lower risks of stroke recurrence within 90 days in younger patients (HR 0.68, 95% CI 0.51 to 0.91, p=0.008)”
Human trialCYP2C19 loss-of-function alleles, minor stroke or high-risk TIA90 days
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial
Stroke and vascular neurologyJan 30, 2024